Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Bullboard Posts
Post by FactFinder1994on Mar 14, 2016 11:12am
180 Views
Post# 24655394

Marketing

Marketing Based on numbers provided current PMX usage globally (over 20,000 patients annually at $20K USD/patient (as per Spectral Investor Presentation). This current annual revenue is equivalent to over $500 million Canadian. Now, today sales are being realized by Toray and its distributors, but of course we (Spectral Medical Shareholders) own the rights to the largest healthcare market in the world (USA). The current Market Cap of Spectral is approx. $160 Million CAD. This Canadian Under the Radar play has about run its course. A $5+ Billion dollar annual revenue opportunity (with addition of EAA & SAM Pump), and this company is valued at $160 Million (had to point it out twice). Hard to imagine Shareholders allowing the inactivity in bringing attention to this opportunity to continue for much longer, as it is a grossly under told story especially in the USA.
Bullboard Posts